CJC-1295 + GHRP-2 (10mg Blend Vial) Dosage Protocol

CJC-1295 + GHRP-2 (10 mg Blend) Dosage Protocol

Quickstart Highlights

CJC-1295 is a long-acting GHRH analog that can elevate GH levels 2–10× baseline for approximately 6 days and increase IGF-1 by 1.5–3× for 9–11 days[1]. GHRP-2 is a ghrelin-mimetic secretagogue with a plasma half-life of ~30 minutes that triggers rapid GH pulses peaking within ~25 minutes of administration[3]. Combining these peptides leverages GHRP-2’s acute pulsatile release with CJC-1295’s sustained action. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

  • Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration (1 unit ≈ 33.3 mcg).
  • Typical daily range: 100–300 mcg once daily (gradual titration).
  • Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
  • Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F) for long-term; after reconstitution, refrigerate and use within 2–4 weeks.
CJC-1295 + GHRP-2 Vial

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Week Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–2 150 mcg (0.15 mg) 4.5 units (0.045 mL)
Weeks 3–12 300 mcg (0.30 mg) 9 units (0.09 mL)

Frequency: Inject once daily subcutaneously, preferably in the evening or ~30–60 minutes before bedtime to coincide with the body’s nocturnal GH peak[6]. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Advanced / Twice-Daily Approach (3 mL = ~3.33 mg/mL)

Some protocols split the daily dose into two administrations (morning upon waking, fasted; and evening before bed) to enhance GH pulsatility[1]. Ensure doses are at least 3–8 hours apart to avoid overlapping GH pulses.

Week Dose per Injection (mcg) Units (per injection) (mL) Total Daily (mcg)
Weeks 1–2 100 mcg (0.10 mg) 3 units (0.03 mL) 200 mcg
Weeks 3–12 150 mcg (0.15 mg) 4.5 units (0.045 mL) 300 mcg

For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration (once-daily schedule).

  • Peptide Vials (CJC-1295 + GHRP-2, 10 mg each):

    • 8 weeks ≈ 2 vials
    • 12 weeks ≈ 3 vials
    • 16 weeks ≈ 4 vials
  • Insulin Syringes (U-100):

    • Per week: 7 syringes (1/day)
    • 8 weeks: 56 syringes
    • 12 weeks: 84 syringes
    • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.

    • 8 weeks (2 vials): 6 mL → 1 × 10 mL bottle
    • 12 weeks (3 vials): 9 mL → 1 × 10 mL bottle
    • 16 weeks (4 vials): 12 mL → 2 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.

    • Per week: 14 swabs (2/day)
    • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
    • 12 weeks: 168 swabs → recommend 2 × 100-count boxes
    • 16 weeks: 224 swabs → recommend 3 × 100-count boxes
CJC-1295 + GHRP-2 Vial
View Supplier
Insulin Syringes
View Supplier
Bacteriostatic Water
View Supplier
Alcohol Pads
View Supplier

Protocol Overview

Concise summary of the once-daily regimen.

  • Goal: Support enhanced GH pulsatility and sustained IGF-1 elevation over a defined research period[1].
  • Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
  • Dose Range: 100–300 mcg daily (total blend) with gradual titration.
  • Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested daily titration approach.

  • Start: 100–150 mcg daily for Weeks 1–2 to allow acclimatization[2].
  • Target: 250–300 mcg daily by Weeks 3–12.
  • Frequency: Once per day (subcutaneous), preferably evening/bedtime.
  • Cycle Length: 8–12 weeks; optional extension to 16 weeks.
  • Timing: Inject on an empty stomach; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality[9][10].

  • Lyophilized: Refrigerate at 2–8 °C (35.6–46.4 °F); freeze at −20 °C (−4 °F) for long-term storage exceeding several months.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks for optimal potency.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.
  • If longer storage of reconstituted solution is needed, aliquot into sterile containers and freeze once; avoid repeated freeze–thaw.

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes for each injection; dispose in a sharps container[7].
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
  • Inject slowly on an empty stomach; GHRP-2’s GH response may be blunted by elevated blood glucose[4].
  • Document daily dose and site rotation to maintain consistency.
  • No post-cycle therapy is required; GH and IGF-1 levels return to baseline after cessation[1].

How This Works

CJC-1295 is a tetrasubstituted GHRH(1–29) analog engineered for extended half-life (~6–8 days) via protection from enzymatic degradation and reversible albumin binding[1]. A single dose can sustain elevated GH for approximately 6 days and IGF-1 elevation for 9–11 days. GHRP-2 is a synthetic hexapeptide ghrelin-mimetic that binds the GH secretagogue receptor (GHS-R1a), triggering acute GH pulses that peak within ~25 minutes[3]. Combining CJC-1295’s sustained GHRH signaling with GHRP-2’s rapid secretagogue action produces synergistic GH release that exceeds either peptide alone[6].

Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

  • Sustained elevation of GH and IGF-1 levels over extended periods with once-daily or even less frequent dosing[1].
  • Long-term pediatric studies (8 months) reported no significant adverse effects or toxicities from GHRP-2 therapy[2].
  • GHRP-2 may transiently increase appetite due to ghrelin-like activity[4].
  • Mild, transient elevations in ACTH, cortisol, and prolactin may occur shortly after injection but remain within physiological ranges[5].
  • CJC-1295 at higher doses may cause transient vasodilatory effects such as facial flushing or brief lightheadedness[1].
  • Occasional mild injection-site reactions (redness, itching) may occur with subcutaneous administration.

Lifestyle Factors

Complementary strategies for best outcomes.

  • Pair with a balanced, protein-forward diet tailored to energy and recovery needs.
  • Combine resistance training and aerobic activity to complement GH-mediated anabolic and metabolic effects.
  • Prioritize quality sleep; nocturnal GH secretion is enhanced by adequate rest.
  • Inject on an empty stomach or after fasting for 2–3 hours; carbohydrate-rich meals may attenuate GHRP-2’s GH response[4].

Injection Technique

General subcutaneous guidance from clinical best-practice resources[7][8].

  • Clean the vial stopper and skin with alcohol; allow to dry.
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[7].
  • Do not aspirate for subcutaneous injections; inject slowly and steadily[8].
  • Rotate sites systematically (abdomen, thighs, upper arms) to avoid local tissue changes[11].
  • Withdraw the needle at the same angle; dispose immediately in a sharps container.

Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

References


  • J Clin Endocrinol Metab (2006)
    — Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting GHRH analog, in healthy adults
    View Source

  • J Clin Endocrinol Metab (1998)
    — Mericq V et al. Effects of eight months treatment with graded doses of GHRP in GH-deficient children
    View Source

  • J Clin Endocrinol Metab (1998)
    — Pihoker C et al. Pharmacokinetics and pharmacodynamics of GHRP-2: a phase I study in children
    View Source

  • J Clin Endocrinol Metab (2005)
    — Laferrère B et al. GHRP-2, like ghrelin, increases food intake in healthy men
    View Source

  • Peptides (1997)
    — Arvat E et al. Effects of GHRP-2 and hexarelin on GH, prolactin, ACTH, and cortisol levels in man
    View Source

  • WADA Technical Document (2019)
    — Testing guide for Growth Hormone Releasing Factors (GHRFs), Version 2.0
    View Source

  • CDC
    — Vaccine administration: subcutaneous route (angle/site; no aspiration)
    View Source

  • CDC (Subcut Injection PDF)
    — Technique diagram and site guidance for subcutaneous injections
    View Source

  • Bachem Technical Bulletin
    — Handling and storage guidelines for peptides
    View Source

  • Sigma-Aldrich Technical Guide
    — Handling and storage of synthetic peptides
    View Source

  • NCBI Bookshelf
    — Best practices for injection (asepsis, preparation, and administration)
    View Source

  • Subcutaneous Drug Injection Review (PMC)
    — Pharmacologic considerations of the subcutaneous route
    View Source

  • Pure Lab Peptides
    — CJC-1295 + GHRP-2 (10 mg Blend) product page (quality and batch documentation)
    View Source